%0 Journal Article
%A Mair, Maximilian J
%A Hartenbach, Sabrina
%A Tomasich, Erwin
%A Maas, Sybren L N
%A Bosch, Sarah A
%A Widhalm, Georg
%A Eckert, Franziska
%A Sahm, Felix
%A Hainfellner, Johannes A
%A Hartenbach, Markus
%A Berghoff, Anna S
%A Preusser, Matthias
%A Albert, Nathalie L
%T Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.
%J European journal of nuclear medicine and molecular imaging
%V 52
%N 8
%@ 1619-7070
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2025-00402
%P 2771-2781
%D 2025
%Z 2025 Jul;52(8):2771-2781
%X High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2
%K Brain tumour (Other)
%K Fibroblast activating protein (Other)
%K Meningioma (Other)
%K Somatostatin receptor (Other)
%K Theranostics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39969538
%R 10.1007/s00259-025-07075-8
%U https://inrepo02.dkfz.de/record/298982